

include the following details-

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	21 February 2025
Date of last disclosure:	17 September 2024
Division or contact manager string displacers	
Director or senior manager giving disclosure Full name(s):	Crohom Andrew Mel con
	Graham Andrew McLean
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director
Summary of acquisition or disposal of relevant interest (excluding specified derivation)	ives)
Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest
(-)	Deficitoral interest
For that relevant interest-	
Number held in class before acquisition or disposal:	1,900 Ordinary Shares
Number held in class after acquisition or disposal:	2,900 Ordinary Shares
· · · · · · · · · · · · · · · · · · ·	Graham Andrew McLean and Linda Farrell as
Current registered holder(s):	trustees of McLean Superfund A/C
Registered holder(s) once transfers are registered:	Graham Andrew McLean and Linda Farrell as trustees of McLean Superfund A/C
Summary of acquisition or disposal of specified derivatives relevant interest (if appl	icable)
Type of affected derivative:	
Class of underlying financial products:	
olass of underlying interioral products.	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying	
financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
·	•
Details of transactions requiring disclosure-	
Date of transaction:	17 February 2025
Nature of transaction:	Purchase of Ordinary Shares
	. a.ondoo or Oramary Ondros
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the	
acquisition or disposal. If the consideration was not in cash and cannot be readily by	
converted into a cash value, describe the consideration:	AUD 32.3000 per Ordinary Share
Number of financial products to which the transaction related:	1,000 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior	
managers from trading during any period without written clearance (a closed period)	

Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	
Nature of relevant interest:	
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying	
financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the	
underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the	
relevant interest in the derivative:	
Certification	
I, certify that, to the best of my knowledge and belief, the information contained in this	
disclosure is correct and that I am duly authorised to make this disclosure by all	
persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Palene traverel
Date of signature:	21 February 2025
Name and title of authorised person:	Raelene Leonard,
·	General Counsel & Company Secretary